Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Vericel Corporation (VCEL)
P/E ratio as of 2023: -532.58
According to Vericel Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -532.58. At the end of 2022 the company had a P/E ratio of -74.30.
P/E ratio history for Vericel Corporation from 1996 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -532.58 |
| 2022 | -74.30 |
| 2021 | -244.46 |
| 2020 | 487.58 |
| 2019 | -97.20 |
| 2018 | -86.05 |
| 2017 | -10.52 |
| 2016 | -3.54 |
| 2015 | -3.75 |
| 2014 | -1.78 |
| 2013 | -0.62 |
| 2012 | -1.76 |
| 2011 | -3.57 |
| 2010 | -3.57 |
| 2009 | -1.67 |
| 2008 | -2.37 |
| 2007 | -9.10 |
| 2006 | -8.58 |
| 2005 | -24.71 |
| 2004 | -6.32 |
| 2003 | -5.38 |
| 2002 | -1.91 |
| 2001 | -8.27 |
| 2000 | -5.98 |
| 1999 | -1.74 |
| 1998 | -2.91 |
| 1997 | -5.61 |
| 1996 | -6.54 |